| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine, namely paediatrics, pulmonology, and covers treatment of recurrent stenosing laryngotracheistis in children. It is enabled by determination of extent of disbiotic conditions of nasopharynx and oropharynx membrane. The first extent requires introduction of Bronchomunal, Bifiform, Fenspirid and retinol acetate, while in the second extent, Ribomunyl, Bifiform, Fenspirid, Triovit and Phenibut are prescribed. ^ EFFECT: method provides selection of optimum treatment regimen considering extent of nasopharynx and oropharynx membrane disbiosis, normalised indices of breathing function and airway sensitivity. ^ 2 dwg, 5 tbl, 3 ex
|
